AUTHOR=Dawidczyk Charlene M. , Russell Luisa M. , Searson Peter C. TITLE=Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments JOURNAL=Frontiers in Chemistry VOLUME=2 YEAR=2014 URL=https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2014.00069 DOI=10.3389/fchem.2014.00069 ISSN=2296-2646 ABSTRACT=

The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range of factors including circulation time, interactions with the mononuclear phagocyte system, extravasation from circulation at the tumor site, targeting strategy, release from the delivery vehicle, and uptake in cancer cells. Nanotechnology provides the possibility of creating delivery systems where the design constraints are decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing tumor accumulation, and improving efficacy. The physico-chemical properties of nanoparticle-based delivery platforms introduce additional complexity associated with pharmacokinetics, tumor accumulation, and biodistribution. To assess the impact of nanoparticle-based delivery systems, we first review the design strategies and pharmacokinetics of FDA-approved nanomedicines. Next we review nanomedicines under development, summarizing the range of nanoparticle platforms, strategies for targeting, and pharmacokinetics. We show how the lack of uniformity in preclinical trials prevents systematic comparison and hence limits advances in the field.